Amyotrophic Lateral Sclerosis Assn

About Amyotrophic Lateral Sclerosis Assn

Amyotrophic Lateral Sclerosis Assn directs large-scale funding toward ALS research, patient care, support services, and advocacy, with a strong emphasis on moving work into clinical use. In the recent grants list, that shows up in a $750,000 clinical trial award to Projenx Inc and a $600,000 trial-capacity and clinical trial award to University of Kansas Medical Center Research Institute Inc. The pattern is not limited to trials: the organization also funded drug-development contracts, prevention work, quality-of-care projects, and fellowships, reflecting a program mix that reaches from early-stage science to care delivery. Its largest awards in the data include multi-hundred-thousand-dollar commitments to universities, hospitals, research institutes, and biotech companies. The grants also point to a portfolio that includes strategic initiatives and partnership programs alongside project-specific research awards. Recipients range from academic medical centers such as University of Massachusetts Medical School and Massachusetts General Hospital - Research to industry groups such as Aquilus Pharmaceuticals Inc and Libra Therapeutics, showing that the funder backs both institutional research infrastructure and translational development. This is a public charity with national reach and a research-forward funding model built around ALS-specific projects.

What Amyotrophic Lateral Sclerosis Assn Funds

The clearest theme is translational and clinical ALS research. The foundation gave $500,000 to Aquilus Pharmaceuticals Inc for a clinical trial award and $300,000 to Libra Therapeutics for a drug development contract, both aimed at advancing therapies toward patient use. It also supported Myrobalan Therapeutics Inc with a $250,000 drug development contract. A second strand is prevention and early intervention. Regents of the University of Michigan received $349,864 tied in part to a prevention program, while The Trustees of Columbia University in the City of New York received $349,286 with prevention-program support and other research components. The third area is quality and care delivery. Mayo Clinic Arizona received a $400,000 award that included quality-of-care programming, and The Regents of the University of California San Francisco received $250,000 for a quality-of-care program. These awards sit alongside trial-capacity support, showing that the foundation funds both therapeutic development and the systems needed to deliver ALS care and research.

How Amyotrophic Lateral Sclerosis Assn Gives